Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neoadjuvant Operable Breast Cancer × Epirubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 82 Stomach Neoplasms 17 Inflammatory Breast Neoplasms 11 Esophageal Neoplasms 10 Sarcoma 5 Triple Negative Breast Neoplasms 4 Lymphoma, Large B-Cell, Diffuse 4 Carcinoma, Hepatocellular 4 Primary Breast Cancer 3 Ovarian Neoplasms 3 Liver Neoplasms 3 Adenocarcinoma Of Esophagus 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Testicular Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Hemangiosarcoma 2 Gallbladder Neoplasms 2 Chondrosarcoma 2 Carcinoma, Ductal, Breast 2 Bile Duct Neoplasms 2 Adenocarcinoma 2 Women With Primary Breast Cancer 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma, Clear Cell 1

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡